z-logo
open-access-imgOpen Access
Challenges in management of unusual acquired factor V deficiency
Author(s) -
Kiyoshi Takemoto,
Osamu Hamada,
Koichi Kitamura,
Naoki Fujiwara,
Yoshitaka Miyakawa
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000015259
Subject(s) - medicine , factor xi , fresh frozen plasma , coagulopathy , ecchymosis , bleeding diathesis , factor v , coagulation , methylprednisolone , clotting factor , factor x , factor ix , coagulation testing , gastroenterology , surgery , thrombosis , platelet , thrombin
Rationale: Acquired inhibitors of coagulation are antibodies that either inhibit the activity or increase the clearance of a clotting factor. Acquired factor V deficiency is a rare coagulation disorder, and it can sometimes be life threatening. Patient concerns: We describe a case of a 90-year-old Japanese male with acquired factor V deficiency. He was previously misdiagnosed with congenital factor V deficiency when he presented with hemoptysis and a negative factor V inhibitor test result at a different hospital 5 years earlier. Coagulopathy recurred with ecchymosis when he sustained a bruise after falling on a bush. Diagnosis: Although the factor V inhibitor test result was negative and a mixing study suggested a deficiency pattern, we diagnosed the patient with acquired factor V deficiency on the basis of no history of bleeding diathesis, a lack of response to multiple fresh frozen plasma transfusion, and clinical response to corticosteroid therapy. Interventions: Intravenous methylprednisolone was administered at 500 mg/day for 3 days, followed by oral prednisolone at 1 mg/kg/day. Outcomes: Coagulation test results improved and symptoms resolved 2 weeks after corticosteroid administration. Lessons: This case report suggests that clearance-facilitating antibodies exist without the presence of neutralizing inhibitors. When patients present with coagulation factor V deficiency in the absence of coagulation inhibitors, acquired factor V deficiency should also be considered.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here